scholarly journals The Diagnostic Value of18F-FDG PET/CT in Association with Serum Tumor Marker Assays in Breast Cancer Recurrence and Metastasis

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Ying Dong ◽  
Haifeng Hou ◽  
Chunyan Wang ◽  
Jing Li ◽  
Qiong Yao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Imaging Techniques ◽  
Radical Mastectomy ◽  
Serum Levels ◽  
Ca 125 ◽  
Clinical Value ◽  
Pet Ct ◽  
Fdg Pet Ct

Background. After initial treatment of breast cancer (BC), monitoring locoregional recurrence and distant metastases is a great clinical challenge.Objective. To evaluate the efficacy of PET/CT in association with serum tumor makers in BC follow-up.Methods. Twenty-six women with a history of modified radical mastectomy were evaluated by18F-FDG PET/CT. The results of PET/CT were compared with those of conventional imaging techniques (CITs) (including mammography, chest radiography, CT, MRI, ultrasound, and bone scintigraphy). Serum tumor markers of CEA, CA 125, and CA 15-3 in the BC patients were also analyzed in association with the results of PET/CT.Results. Compared with CITs, PET/CT was more sensitive to detect the malignant foci and had better patient-based sensitivity and specificity. The mean CA 15-3 serum level was significantly higher in the confirmed positive patients of PET/CT results than in the confirmed negative ones, while there were no significant differences in the serum levels of CEA and CA 125 of both groups.Conclusion. PET/CT is a highly efficient tool for BC follow-up compared with CITs. The high serum levels of CA 15-3 in confirmed positive PET/CT patients indicated the clinical value of CA 15-3 in BC follow-up.

scholarly journals Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer

2016 ◽  
Vol 37 (6) ◽  
pp. 602-608
Author(s):  
Mehdi Taghipour ◽  
Sara Sheikhbahaei ◽  
Tyler J. Trahan ◽  
Rathan M. Subramaniam
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Ct Scans ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Post Therapy

The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques

2010 ◽  
Vol 36 (4) ◽  
pp. 387-392 ◽  
Author(s):  
T.S. Aukema ◽  
E.J.Th. Rutgers ◽  
W.V. Vogel ◽  
H.J. Teertstra ◽  
H.S. Oldenburg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Imaging Techniques ◽  
Cancer Recurrence ◽  
Breast Cancer Recurrence ◽  
Conventional Imaging ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Study: Role of FDG PET/CT imaging in follow up of Breast Cancer: Our Institutional Experience

2019 ◽  
Vol 3 (1) ◽  
pp. 55-58
Author(s):  
Selma Agić-Bilalagić ◽  
Amela Begić ◽  
Miran Hadćiahmetović ◽  
Šejla Cerić ◽  
Amila Bašić ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Ct Imaging ◽  
Pet Ct ◽  
Institutional Experience ◽  
Fdg Pet Ct

Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer

2011 ◽  
Vol 52 (9) ◽  
pp. 1009-1014 ◽  
Author(s):  
Steffen Hahn ◽  
Till Heusner ◽  
Sherko Kümmel ◽  
Angelika Köninger ◽  
James Nagarajah ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Whole Body ◽  
Reference Standard ◽  
Breast Cancer Patients ◽  
Pet Ct ◽  
Fdg Pet Ct

Background Bone scintigraphy is the standard procedure for the detection of bone metastases in breast cancer patients. FDG-PET/CT has been reported to be a sensitive tool for tumor staging in different malignant diseases. However, its accuracy for the detection of bone metastases has not been compared to bone scintigraphy. Purpose To compare whole-body FDG-PET/CT and bone scintigraphy for the detection of bone metastases on a lesion basis in breast cancer patients. Material and Methods Twenty-nine consecutive women (mean age 58 years, range 35-78 years) with histologically proven breast cancer were assessed with bone scintigraphy and whole-body FDG-PET/CT. Twenty-one patients (72%) were suffering from primary breast cancer and eight patients (28%) were in aftercare with a history of advanced breast cancer. Both imaging procedures were assessed for bone metastases by a radiologist and a nuclear medicine physician. Concordant readings between bone scintigraphy and FDG-PET/CT were taken as true. Discordant readings were verified with additional MRI imaging in all patients and follow-up studies in most patients. Results A total of 132 lesions were detected on bone scintigraphy, FDG-PET/CT or both. According to the reference standard, 70/132 lesions (53%) were bone metastases, 59/132 lesions (45%) were benign, and three lesions (2%) remained unclear. The sensitivity of bone scintigraphy was 76% (53/70) compared to 96% (67/70) for FDG-PET/CT. The specificity of bone scintigraphy and FDG-PET/CT was 95% (56/59) and 92% (54/59), respectively. According to the reference standard bone metastases were present in eight out of the 29 patients (28%), whereas 20 patients (69%) were free of bone metastases. One (3%) patient had inconclusive readings on both modalities as well as on MRI and follow-up studies. Bone scintigraphy and FDG-PET/CT correctly identified seven out of eight patients with bone metastases and 20 out of 20 patients free of metastases. Conclusion On a lesion-basis whole-body FDG-PET/CT is more sensitive and equally specific for the detection of bone metastases compared with bone scintigraphy.

scholarly journals The clinical utility of FDG-PET/CT in follow up and restaging of breast cancer patients

2013 ◽  
Vol 44 (4) ◽  
pp. 937-943 ◽  
Author(s):  
Sally Emad-Eldin ◽  
Omar Abdelaziz ◽  
Marc Harth ◽  
Manar Hussein ◽  
Nour-Eldin Nour-Eldin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Clinical Utility ◽  
Breast Cancer Patients ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Melanom in izolirane metastaze v vranici-prikaz primera in pregled literature

2015 ◽  
Vol 84 (6) ◽  
Author(s):  
Jerica Škedelj ◽  
Ivana Žagar ◽  
Marko Snoj
Keyword(s):  
Fdg Pet ◽  
Malignant Disease ◽  
Imaging Techniques ◽  
Rare Event ◽  
Stage Iv ◽  
Pet Ct ◽  
S 100 ◽  
Fdg Pet Ct

Background. Metastases to the spleen are considered a rare event generally occurring during the late stage of malignant disease. Isolated metastases are even rarely described. In the past years the number of reported cases in literature has risen mainly due to the improvements of the imaging techniques and the use of FDG-PET/CT in the follow-up of the patients with malignant disease. Even though melanoma can disseminate to any organ, metastases to spleen, found during life, are rare. Moreover, proven isolated metastases in the spleen are even seldomly described. Case report. We report a case of 61-year-old man with known skin melanoma treated in our Institute from 2009. During the regular follow up raised values of S-100 marker and isolated lesions in the spleen found on FDG-PET/CT were described. Due to isolated metastatic disease, splenectomy was indicated.Conclusion. Patients with stage IV. melanoma have poor prognosis, the median survival is estimated to six months. According to studies, metastasectomies for isolated metastases in solid organs can significantly improve survival of these patients. In melanoma patients with FDG-PET/CT proven isolated metastases to the spleen, splenectomy can significantly improve their survival and quality of life.  

scholarly journals Clinical value of 18F-FDG PET/CT in diagnosis and follow-up of primary gastric lymphoma

2014 ◽  
Vol 22 (33) ◽  
pp. 5144
Author(s):  
Wen-Jing Tang ◽  
Wei-Fu Lv ◽  
Shi-Cun Wang ◽  
Bo Pan ◽  
Ge-Liang Xu
Keyword(s):  
Fdg Pet ◽  
Gastric Lymphoma ◽  
Clinical Value ◽  
Primary Gastric Lymphoma ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Goblet cell carcinomas of the appendix: rare but aggressive neoplasms with challenging management

2018 ◽  
Vol 7 (2) ◽  
pp. 268-277 ◽  
Author(s):  
Ashley K Clift ◽  
Oskar Kornasiewicz ◽  
Panagiotis Drymousis ◽  
Omar Faiz ◽  
Harpreet S Wasan ◽  
...  
Keyword(s):  
Goblet Cell ◽  
Fdg Pet ◽  
Right Hemicolectomy ◽  
Ca 125 ◽  
Neuroendocrine Neoplasms ◽  
Class A ◽  
Heated Intraperitoneal Chemotherapy ◽  
Pet Ct ◽  
Fdg Pet Ct

Goblet cell carcinomas (GCC) are a rare, aggressive sub-type of appendiceal tumours with neuroendocrine features, and controversy exists with regards to therapeutic strategy. We undertook a retrospective review of GCC patients surgically treated at two tertiary referral centres. Clinical and histopathological data were extracted from a prospectively maintained database. Survival analyses utilised Kaplan–Meier methodology. Twenty-one patients were identified (9 females). Median age at diagnosis was 55 years (range 32–77). There were 3, 6 and 9 grade 1, 2 and 3 tumours, respectively. One, 10, 5 and 5 patients had stage I, II, III and IV disease at diagnosis, respectively. There were 8, 10 and 3 Tang class A, B and C tumours, respectively. Index operation was appendectomy (n = 12), right hemicolectomy (n = 6) or resections including appendix/right colon, omentum and the gynaecological system (n = 3). Eight patients underwent completion right hemicolectomy. Surgery for recurrence included small bowel resection (n = 2), debulking with peritonectomy and heated intraperitoneal chemotherapy, and hysterectomy and bilateral salpingo-oophorectomy (all n = 1). Median follow-up was 30 months (range 2.5–123). One-, 3- and 5-year OS was 79.4, 60 and 60%, respectively. Mean OS (1-, 3-, and 5-year OS) for Tang class A, B and C tumours were 73.1 months (85.7, 85.7, 51.4%), 83.7 months (all 66.7%) and 28.5 months (66.7, 66.7%, not reached), respectively. Chromogranin A/B and 68Ga-DOTATATE PET/CT were not useful in follow-up, but CEA, CA 19-9, CA 125 and 18F-FDG PET/CT identified tumour recurrence. GCC must be clearly discriminated from relatively indolent appendiceal neuroendocrine neoplasms. 18F-FDG PET/CT and CEA/CA19-9/CA 125 are useful in detecting recurrence of GCC.

Sign in / Sign up

Export Citation Format

Share Document